AOBiome, LLC is aiming for what it sees as a relatively underserved market of patients in the atopic dermatitis market, hoping to address disease appearance as well as itching, as it looks toward moving its bacterial-based topical drug, B244, into Phase III after a successful Phase IIb study.
AOBiome Targets Atopic Dermatitis Niche With Bacteria-Based Drug
While the atopic dermatitis market overall is crowded, the company sees a market opportunity for a drug that addresses both appearance and itching, as well as having favorable safety and ease of use.
